Biomerica (NASDAQ:BMRA) vs. Oruka Therapeutics (NASDAQ:ORKA) Financial Comparison

Biomerica (NASDAQ:BMRA) and Oruka Therapeutics (NASDAQ:ORKA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, risk, institutional ownership, profitability, analyst recommendations and valuation.

Analyst Ratings

This is a summary of current ratings and price targets for Biomerica and Oruka Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biomerica	0	0	0	0	0.00
Oruka Therapeutics	0	0	6	2	3.25

Oruka Therapeutics has a consensus target price of $43.17, suggesting a potential upside of 79.56%. Given Oruka Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Oruka Therapeutics is more favorable than Biomerica.

Valuation & Earnings

This table compares Biomerica and Oruka Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biomerica	$5.41 million	1.09	-$5.98 million	($0.37)	-0.94
Oruka Therapeutics	N/A	N/A	-$5.34 million	($6.26)	-3.84

Oruka Therapeutics has lower revenue, but higher earnings than Biomerica. Oruka Therapeutics is trading at a lower price-to-earnings ratio than Biomerica, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Biomerica has a beta of -1.13, suggesting that its stock price is 213% less volatile than the S&P 500. Comparatively, Oruka Therapeutics has a beta of 0.87, suggesting that its stock price is 13% less volatile than the S&P 500.

Insider and Institutional Ownership

22.3% of Biomerica shares are held by institutional investors. Comparatively, 56.4% of Oruka Therapeutics shares are held by institutional investors. 15.0% of Biomerica shares are held by insiders. Comparatively, 22.7% of Oruka Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Biomerica and Oruka Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Biomerica	-111.89%	-84.62%	-62.72%
Oruka Therapeutics	N/A	-79.39%	-76.69%

Summary

Oruka Therapeutics beats Biomerica on 10 of the 14 factors compared between the two stocks.

About Biomerica

Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops products to indicate if a person has been infected by COVID-19. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.

About Oruka Therapeutics

ARCA biopharma, Inc., a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products. The Company’s business focus combines expertise in cardiovascular pathophysiology, molecular genetics, clinical development and product commercialization. It is currently developing Gencaro (bucindolol hydrochloride), a cardiovascular drug for the treatment of chronic heart failure. The company is based in Broomfield, Colorado.